Loading stock data…
Loading stock data…
Earnings reportIn 6 days
Wednesday, July 22 · After hours · EPS est. -0.904
Confirmed dates from data providers — they can still change. Information only, not investment advice.
US$5.45
Get one email when IMA crosses your level. Checked every 15 minutes during market hours.
▼ -0.56 (-9.32%)down today
USD · data via Finnhub · delayed/cached up to 1–5 min
Get an AI-written, balanced deep-dive — performance, valuation, technicals, and the bull vs. bear case. Sign in to get started.
RSI (14-day)
38.3
NeutralAbove 70 can signal overbought; below 30, oversold.
MACD
0.03
Bearish momentumMACD below its signal line (0.06).
50-day average
5.76
Price belowShort-term trend reference.
200-day average
6.51
Price belowLong-term trend reference.
Daily values · indicators are descriptive, not trading advice
Healthcare · Biotechnology
ImageneBio, Inc. is a clinical-stage biotechnology company specializing in the development of therapeutics for immunological, autoimmune, and inflammatory diseases. The company is driven by the mission to transform patient outcomes through innovative medicines that aim to not only control symptoms but also alter the course of serious immune-related conditions. Leveraging both external innovation and its proprietary QuadraTek® platform, ImageneBio is focused on creating differentiated therapies w…
www.inmagenebio.com3 strong buy · 2 buy · 1 hold · 0 sell · 1 strong sell (7 analysts, 2026-07-01)
3 strong buy · 2 buy · 1 hold · 0 sell · 1 strong sell (7 analysts, 2026-06-01)
3 strong buy · 2 buy · 1 hold · 0 sell · 1 strong sell (7 analysts, 2026-05-01)
3 strong buy · 2 buy · 1 hold · 0 sell · 1 strong sell (7 analysts, 2026-04-01)
| Quarter | Estimate | Actual | Result |
|---|---|---|---|
| 2026-05-07 | -0.66 | -0.95 | ✗ Miss |
| 2026-04-21 | 1.52 | 2.16 | ✓ Beat |
| 2026-03-10 | 0.26 | 0.3 | ✓ Beat |
| 2025-11-12 | -1 | -2.91 | ✗ Miss |
| 2025-09-22 | 50.68 | 48.71 | ✗ Miss |
Companies in the same industry, via Finnhub